Ovarian Cancer Diagnostics Market

Ovarian Cancer Diagnostics Market Outlook

This global ovarian cancer diagnostics market analysis by Fact.MR predicts the industry to expand at a robust CAGR of 7% from 2021 to 2031.

Market CAGR (2021-2031)	7%
North America Market Share	45%
Market Value in 2020	US$ 1.3 Bn
Fastest-Growing Markets in APAC Region	China and India

Fact.MR, a market research and competitive intelligence provider, has performed detailed analysis of the industry and researched all the factors that affect market growth. As per the study, the ovarian cancer diagnostics market amassed revenue worth US$ 1.3 Bn in 2020.

Demand Analysis of Ovarian Cancer Diagnostics (2016 to 2020) Vs Market Forecasts (2021 to 2031)

Rising geriatric population all over the globe has completely transformed the healthcare industry across the globe. Aging women face the issue of ovarian cancer and as the number of aging women rises the instances of ovarian cancer are becoming more frequent.

Demand for ovarian cancer diagnostics is anticipated to be more as ovarian cancer becomes more common in the wake of rising aging women population. The need for accurate and in time diagnostic for ovarian cancer is increasing. Government backed initiatives and research is focusing on developing diagnostic methods that could detect the cancer in its early stages as the present diagnostic methods detect it when it has already spread at an advanced stage.

Increasing awareness, rising focus of government and other medical organizations to provide easy and in-time diagnosis of ovarian cancer are prime factors propelling the industry growth. The ovarian cancer diagnostics market growth to 2031 is estimated to rise at a CAGR of 7%.

What are the Different Types of Ovarian Cancer Diagnostic Imaging Techniques?

Imaging diagnostics play a vital role in ovarian cancer diagnosis and treatment as they allow professionals to explore the extent to which the tumors have spread. Some of the techniques are:

• Ultrasound for Ovarian Cancer Diagnostics
• PET Scan for Ovarian Cancer Diagnostics
• CT Scan for Ovarian Cancer Diagnostics

Demand for CT scan in ovarian cancer diagnostics is expected to increase over the next ten years due to its ability to provide insights on spread of tumor. The demand for PET scan in ovarian cancer diagnostics is expected to be moderate as it is not as commonly used.

What Does the Survey Say About Different Cancer Tests?

Due to the prevalence of different types of cancers and different nature of tumors there are a wide array of tests that can be employed to detect cancer.

Demand for CA 125 test in ovarian cancer diagnostics and HER 2 test is expected to be prominent over the forecast period in comparison to other tests. The sales of HER 2 test for ovarian cancer diagnostics are expected to see a modest growth as other tests gain popularity.

Epithelial tumors are most prominent in ovarian cancer and account for majority of instances hence demand for epithelial tumor diagnostics is substantially higher than the demand for germ cell carcinoma tumor diagnostics and stromal carcinoma tumor diagnostics demand combined.

Which Establishments are Essential for Ovarian Cancer Diagnostics?

Various healthcare establishments utilize ovarian cancer diagnostics for treatments to research. The most prominent are testing laboratories associated with hospitals and research centers.

Demand for ovarian cancer diagnostics in hospital associated labs is expected to be most prominent and predicted to increase as the instances of ovarian cancer rise. The demand for ovarian cancer diagnostics in independent diagnostic laboratories is anticipated to see a major rise as the affordability of equipment and instruments is realized. Independent diagnostic laboratories are increasing in number especially in emerging economies where the healthcare infrastructure is improving.

Demand for ovarian cancer diagnostics in cancer research institutes is expected to see a steady increase as demand for research increases. The demand for ovarian cancer diagnosis instruments is also expected to see a rise as research and developments in the industry progress.

Which Regions are Lucrative Markets for Ovarian Cancer Diagnostics?

This research details the global ovarian cancer diagnostics industry landscape in regions like North America, Latin America, Europe, APAC, and MEA.

North American region is estimated to hold a dominant stake in the global ovarian cancer diagnostics market share. The demand for BRCA test in ovarian cancer diagnostics is anticipated to rise at a positive CAGR of nearly 8% in the region. Europe is expected to account for a modest amount of market share in the global ovarian cancer diagnostics industry.

Demand for ovarian cancer diagnostics in APAC region is predicted to evolve at the fastest CAGR. The growth will majorly be driven by nations like India and China. The lack of awareness about the symptoms and treatments is a major factor that restricts the growth in APAC region.

The MEA region is expected to see relatively slower adoption of ovarian cancer diagnostics owing to the slow adoption of new diagnostic methods and limited healthcare spending potential.

Country-wise Analysis

How is the U.S. Ovarian Cancer Diagnostics Market Expected to Perform over the Decade?

The U.S. is anticipated to hold a dominant market share in the North American region. The demand for ovarian cancer diagnostics in the U.S. is majorly fueled by the increasing geriatric population, rising awareness, and the presence of prominent players. Technological advancements and increasing investments in research initiatives backed by the government also play a vital role in the development of the ovarian cancer diagnostics industry in the U.S.

What are the Trends of Ovarian Cancer Diagnostics in China?

China is expected to see some major changes in ovarian cancer diagnostics industry as it is expected to be one of the countries in APAC region with the fastest CAGR.  While the nation has seen some decrease in cases over the past decade, the number of cases is anticipated to rise as the geriatric population increases over time. Government is placing control policies to curb the deaths and also backing research to promote ovarian cancer diagnostics.

Category-wise Analysis

How are Sales of KRAS Mutation Tests in Ovarian Cancer Diagnostics Shaping Up?

Research in developing new diagnostic tests and methods has increased substantially and researchers are coming up with new and advanced tests to diagnose tumors. Increased emphasis on genetic counseling is one of the major factors that is favoring the penetration of tests like KRAS mutation, HER 2, BRCA, etc. As research advances the penetration of these tests is expected to increase and the sales are anticipated to grow at a steady rate.

COVID-19 Pandemic Evaluation

The global pandemic, which started in early 2020, has affected the world and has exposed critical loopholes in the worldwide healthcare infrastructure. The demand for bolstering the infrastructure and rectifying the loopholes is increased substantially as the pressure from people has risen. Governments are now taking initiatives to fund research and develop efficient and effective healthcare measures to ensure public safety.

A similar trend is expected to be followed in the case of ovarian cancer diagnostics as research for early-stage detection is gaining traction due to popular demand.

Competitive Landscape

Latest innovations in ovarian cancer diagnostics are much needed in the industry to spot cancer in its initial stages and treat it at that stage without causing much damage to the internal organs of the affected person. Top manufacturers of ovarian cancer diagnosis instruments are investing in research and development of devices and instruments that would aid in the diagnosis and treatment more effectively and efficiently.

• In August 2020, Chinese researchers from Suzhou Institute of Biomedical Engineering and Technology pioneered a non-invasive method that would aid in identifying and differentiating the types of ovarian cancer. It can differentiate between type I and type II ovarian cancer with an accuracy of 83%.
• MiRxes on the basis of a recent funding round has announced that it would be developing new assays for breast cancer, ovarian cancer, liver cancer and other cancers that would utilise the disease biomarkers revealed in the process of discovery. This part of company’s expansion of product portfolio with additional PCR tests.
• GinaLife an Israeli femtech start-up who is utilising AI and data science to identify women health issues at an early stage is pioneering an ovarian cancer test that would help with early detection of the condition. The test would enable women to examine themselves as it would be made easily accessible and available to women across the world. As of now it is just being tested in-clinic.

Ovarian Cancer Diagnostics Industry Report Scope

Attribute	Details
Forecast Period	2021-2031
Historical Data Available for	2016-2020
Market Analysis	Units for Volume and US$ Mn for Value
Key Regions Covered	North America Latin America Europe APEJ MEA
Key Countries Covered	United States Canada Brazil Mexico Germany U.K. France Spain Italy China Japan South Korea India Indonesia Malaysia Singapore Australia New Zealand Turkey South Africa and GCC Countries
Key Market Segments Covered	Cancer Type Test Type End User Region
Key Companies Profiled	Abbott Laboratories Roche Holding A.G. Thermo Fisher Scientific Inc. Laboratory Corporation of America Holdings Luminex Corporation Myriad Genetics Inc.
Pricing	Available upon Request

Key Segments of Ovarian Cancer Diagnostics Industry Survey

• By Cancer Type:

  • Epithelial Tumor Diagnostics
  • Germ Cell Carcinoma Tumor Diagnostics
  • Stromal Carcinoma Tumor Diagnostics

• By Test Type:

  • CA 125 Test for Ovarian Cancer Diagnostics
  • HER 2 Test for Ovarian Cancer Diagnostics
  • BRCA Test for Ovarian Cancer Diagnostics
  • CEA Test for Ovarian Cancer Diagnostics
  • ER & PR Test for Ovarian Cancer Diagnostics
  • KRAS Mutation Test for Ovarian Cancer Diagnostics
  • Others

• By End User:

  • Hospital Associated Labs
  • Independent Diagnostic Laboratories
  • Cancer Research Institutes
  • Others